drugset / Trial / NCT00693069
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
Phase 3
Completed
120 enrolled
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Adequate platelet inhibition before percutaneous coronary intervention (PCI) reduces peri-procedural and long-term ischemic complications. Documented reduced response to clopidogrel has been associated with subsequent major adverse cardiovascular events. Strategies to optimize platelet inhibition pre-PCI are under investigation. This study sought to evaluate the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective PCI.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Clopidogrel | Small molecule | 150 mg | — |
| Subject | Clopidogrel | Small molecule | 300 mg | — |
| Subject | Clopidogrel | Small molecule | 600 mg | — |